Skip to main content

In medical-surgical ICU patients, major bleeding is common but independent of heparin prophylaxis

Introduction

Bleeding frequently complicates critical illness. Our objectives were to describe the incidence, locations and predictors of major bleeding in patients with low risk of bleeding receiving thromboprophylaxis.

Methods

In the PROTECT trial comparing dalteparin to unfractionated heparin for thromboprophylaxis in medical-surgical ICU patients, research coordinators used a validated ICU-specific tool to describe the site and severity of each bleeding event, which was reevaluated by two independent blinded adjudicators. Patients with trauma, orthopedic surgery or neurosurgery were excluded. Major bleeding was defined as life threatening, occurring in critical sites, requiring ≥2 units of red blood cells or an invasive intervention, or associated with an unexplained decrease in systolic blood pressure (≥20 mmHg) or increase in heart rate (≥20 beats/minute). We used Cox proportional hazard models adjusting for age, APACHE II, reason for ICU admission, end-stage renal disease, drugs affecting coagulation, coagulation parameters and life-support interventions to identify predictors of bleeding.

Results

Among 3,746 patients, 208 had major bleeding (5.6%, 95% CI 4.9 to 6.3%). The commonest bleeding sites were: gastrointestinal tract (51.9%), surgical site (30.3%), respiratory tract (15.9%), retroperitoneal (8.2%) and intracranial (3.4%). Independent predictors of major bleeding (expressed as hazard ratio with 95% CI) were: prolonged activated partial thromboplastin time (aPTT) (1.10, 1.05 to 1.14 per 10-second increase), thrombocytopenia (1.16, 1.09 to 1.24 per 50 × 109/l decrease in platelet count), therapeutic heparin (3.26, 1.72 to 6.17), anti-platelet agents (that is, acetylsalicylic acid and/or clopidogrel) (1.38, 1.02 to 1.88), renal replacement therapy (1.75, 1.20 to 2.56) and surgery in the preceding 3 days (1.64, 1.01 to 2.65). Prophylactic dalteparin in the preceding 3 days was not associated with bleeding.

Conclusion

Major bleeding occurred in 5.6% of medical-surgical ICU patients. Prolonged aPTT, thrombocytopenia, therapeutic (but not prophylactic) heparin, anti-platelet agents and recent surgery are potentially modifiable and independent predictors of bleeding.

Author information

Affiliations

Authors

Corresponding author

Correspondence to F Lauzier.

Rights and permissions

This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

Reprints and Permissions

About this article

Cite this article

Lauzier, F., Arnold, D., Rabbat, C. et al. In medical-surgical ICU patients, major bleeding is common but independent of heparin prophylaxis. Crit Care 16, P435 (2012). https://doi.org/10.1186/cc11042

Download citation

Keywords

  • Heparin
  • Clopidogrel
  • Renal Replacement Therapy
  • Major Bleeding
  • Acetylsalicylic Acid